Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New option for chronic graft vs. host

Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.

Key clinical point: The ROCK2-selective inhibitor KD025 shows encouraging activity in cGVHD.

Major finding: Clinical response rates in cohorts 1 and 2 were 65% and 69%, respectively.

Study details: Preliminary findings in 33 patients from a phase 2a trial.

Disclosures: The trial is sponsored by Kadmon. Dr. Lazaryan reported advisory board membership and consultancy for GLyPharma Therapeutic.

Source: Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.

Read the article.

Citation:

Lazaryan A et al. 2018 BMT Tandem Meetings, Abstract 38.

This Week's Must Reads

Caplacizumab approved for adults with aTTP , FDA news release: FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

IVIG versus anti-D in pediatric ITP , Lioger B et al. J Pediatr. 2019; 204:225-33.

Promising treatment for heavy menstrual bleeding , O’Brien SH et al. J Pediatr Adol Gynec. 2019 Feb 4. doi: 10.1016/j.jpag.2019.01.009.

Beware of ICH in severe hemophilia cases , Zwagemaker AF et al. EAHAD 2019, Abstract OR08.

75 exposure days is the magic number in inhibitor risk , van den Berg HM et al. EAHAD 2019, Abstract OR05.

Must Reads in Cellular Therapy

Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301

HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820